Seaport Therapeutics director Denice Torres reported equity-related changes tied to the company’s initial public offering and board compensation. A revocable trust associated with her converted 42,105 shares of Series B Preferred Stock into 13,406 shares of Common Stock on a one-for-one basis upon the IPO closing on May 4, 2026, with no additional consideration.
Separately, she received a stock option grant for 12,258 shares of Common Stock at an exercise price of $18.00 per share. This option expires on April 29, 2036 and will vest in full on April 30, 2027, subject to her continued service.
ARCH Venture Fund XII, L.P., a 10% owner of Seaport Therapeutics, Inc., increased its indirect position through an open-market purchase and preferred stock conversions. On May 4, 2026, ARCH XII bought 1,100,000 shares of common stock at $18.00 per share in an open-market transaction.
On the same date, ARCH XII also converted 2,681,265 shares of Series B Preferred Stock and 2,513,686 shares of Series A-2 Preferred Stock into common stock, eliminating these preferred positions. Following these transactions, ARCH XII indirectly held 6,294,951 shares of Seaport Therapeutics common stock through its fund structure.
Seaport Therapeutics Chief Medical Officer Antony Loebel reported equity-related changes in his holdings. He converted 63,157 shares of Series B Preferred Stock into 20,109 shares of Common Stock on a one‑for‑3.1407 basis, tied to the closing of the company’s initial public offering, and now holds 20,109 common shares directly.
On a separate date, he received a stock option for 63,680 shares of Common Stock at an exercise price of $18.00 per share, expiring on April 29, 2036. These option shares vest in 48 equal monthly installments following April 30, 2026, contingent on his continued service, and represent compensation rather than open‑market trading.
Seaport Therapeutics director Sandra E. Peterson reported her initial holdings of stock options in Seaport Therapeutics, Inc. The filing lists two option grants to buy Common Stock: one covering 12,258 underlying shares at an exercise price of $10.31, and another covering 77,042 underlying shares at $7.39.
For the 12,258-share option, one-third of the underlying shares vested on December 2, 2025, with the rest vesting in 24 equal monthly installments, subject to her continued service. The 77,042-share option is scheduled to vest and become exercisable on February 24, 2027, also subject to continued service, with expiration dates in 2036 and 2034 respectively.
Seaport Therapeutics, Inc. director Sharon Mates has filed an initial Form 3 insider ownership report. The provided data show no reported transactions and no derivative positions, indicating this filing is primarily an administrative disclosure of insider status rather than a record of trading activity.
Seaport Therapeutics director Denice Torres has reported her existing equity awards and preferred shares in a Form 3. She holds stock options tied to 12,258 shares of Common Stock with a $10.31 exercise price expiring on February 23, 2036, and additional options tied to 77,042 shares at a $3.05 exercise price expiring on June 3, 2034. Vesting for these options occurs over time, with one grant beginning to vest on April 28, 2025 and another vesting on February 24, 2027, subject to continued service. A revocable trust associated with her holds Series B Preferred Stock convertible into 13,406 shares of Common Stock without additional payment, and she disclaims beneficial ownership of those trust-held shares except to the extent of any pecuniary interest.
Seaport Therapeutics, Inc. executive Lauren White, the Chief Financial Officer, has filed an initial ownership report that lists her existing equity interests in the company rather than new trades. The filing shows multiple stock option awards and a preferred stock position that can convert into common shares.
White holds stock options directly over 63,680 shares of common stock at an exercise price of $10.31 per share and additional options over 8,331 and 429,840 shares at an exercise price of $7.39 per share, each with long-dated expirations in 2034 and 2036. Vesting schedules extend over several years, with some options already fully vested and others vesting in monthly installments tied to her continued service.
Indirectly, through the Lauren Anne White Living Trust, she has 6,702 shares of Series B Preferred Stock, each convertible into common stock on a one-for-3.1407 basis and automatically convertible into the number of common shares shown upon the closing of the company’s initial public offering, without additional payment. She disclaims beneficial ownership of these preferred shares beyond any pecuniary interest.
Seaport Therapeutics, Inc. reports ARCH-affiliated initial holdings in preferred stock that is convertible into common shares. ARCH Venture Fund XII, L.P. holds Series B Preferred Stock representing 2,681,265 underlying shares of Common Stock and Series A-2 Preferred Stock representing 2,513,686 underlying shares, all as indirect ownership.
Each share of Series A-2 Preferred Stock and Series B Preferred Stock is convertible into Common Stock on a one-for-3.1407 basis at the option of the holder and will automatically convert into the stated numbers of common shares upon the closing of the company’s initial public offering, with no additional consideration and no expiration date. The structure runs through ARCH Venture Partners XII, L.P. and ARCH Venture Partners XII, LLC, and investment committee members Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen disclaim beneficial ownership beyond any pecuniary interest.
Seaport Therapeutics, Inc. General Counsel Lana Gladstein filed an initial ownership report showing derivative stakes in Seaport’s equity. She holds stock options linked to 63,680, 26,533 and 246,760 shares of common stock at exercise prices of $10.31, $7.39 and $3.05 per share, expiring between 2034 and 2036. She also holds Series B Preferred Stock convertible into 33,515 common shares on a one-for-3.1407 basis, which automatically converts into common stock upon the company’s initial public offering without additional payment. Footnotes explain that one option grant is fully vested, while the others vest over four years in monthly installments, contingent on her continued service.